Sign in or create an account to add this stock to your watchlist.
About CytomX Therapeutics (NASDAQ:CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185
Debt
Debt-to-Equity RatioN/A
Current Ratio5.27
Quick Ratio5.27
Price-To-Earnings
Trailing P/E Ratio-22.62
Forward P/E Ratio-17.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.62 million
Price / Sales14.27
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book20.66
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-67.88%
Return on Equity-92.68%
Return on Assets-13.31%
Miscellaneous
Employees93
Outstanding Shares38,960,000
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics (NASDAQ:CTMX) announced its quarterly earnings data on Wednesday, March, 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.45. The biotechnology company had revenue of $27.07 million for the quarter, compared to analysts' expectations of $10.70 million. CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
9 equities research analysts have issued 1-year target prices for CytomX Therapeutics' stock. Their predictions range from $37.00 to $44.00. On average, they expect CytomX Therapeutics' share price to reach $40.1667 in the next twelve months. View Analyst Ratings for CytomX Therapeutics.
What are Wall Street analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
- 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/10/2018)
- 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), TESARO (TSRO), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Evotec A.G. (EVTCY) and Global Blood Therapeutics (GBT).
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
- Mr. Frederick W. Gluck, Co-Founder & Director (Age 83)
- Dr. W. Michael Kavanaugh M.D., Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
- Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
- Prof. Patrick S. Daugherty Ph.D., Founder and Member of Scientific Advisory Board
Has CytomX Therapeutics been receiving favorable news coverage?
Media headlines about CTMX stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.06 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.36 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are CytomX Therapeutics' major shareholders?
CytomX Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.45%), Millennium Management LLC (1.53%), FIL Ltd (1.10%), Redmile Group LLC (0.86%), Spark Investment Management LLC (0.75%) and American Century Companies Inc. (0.53%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.
Which major investors are selling CytomX Therapeutics stock?
CTMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., American Century Companies Inc., Redmile Group LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., JPMorgan Chase & Co. and Schroder Investment Management Group. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.
Which major investors are buying CytomX Therapeutics stock?
CTMX stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, Victory Capital Management Inc., FIL Ltd, Russell Investments Group Ltd., Federated Investors Inc. PA, Spark Investment Management LLC, Citadel Advisors LLC and UBS Group AG. View Insider Buying and Selling for CytomX Therapeutics.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $26.24.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $1.01 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
CytomX Therapeutics (NASDAQ:CTMX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for CytomX Therapeutics in the last 12 months. Their average twelve-month price target is $40.1667, suggesting that the stock has a possible upside of 53.07%. The high price target for CTMX is $44.00 and the low price target for CTMX is $37.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.80 | 2.64 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $40.1667 | $40.1667 | $33.8750 | $33.00 |
| Price Target Upside: | 53.07% upside | 18.14% upside | 48.12% upside | 64.67% upside |
CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History
CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
CytomX Therapeutics (NASDAQ:CTMX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CytomX Therapeutics (NASDAQ CTMX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 75.97%
CytomX Therapeutics (NASDAQ CTMX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/1/2018 | Debanjan Ray | CFO | Sell | 3,000 | $26.52 | $79,560.00 | 7,741 |  |
| 5/1/2018 | Sean A Mccarthy | CEO | Sell | 19,578 | $26.55 | $519,795.90 | 24,221 | |
| 4/2/2018 | Debanjan Ray | CFO | Sell | 3,000 | $28.12 | $84,360.00 | 7,741 | |
| 3/26/2018 | Frederick W Gluck | Director | Sell | 5,000 | $31.93 | $159,650.00 | | |
| 3/2/2018 | Debanjan Ray | CFO | Sell | 33,000 | $29.99 | $989,670.00 | | |
| 3/2/2018 | Frederick W Gluck | Director | Sell | 16,181 | $30.00 | $485,430.00 | | |
| 3/2/2018 | Rachel Humphrey | Insider | Sell | 16,160 | $30.00 | $484,800.00 | 46,394 | |
| 2/28/2018 | Frederick W Gluck | Director | Sell | 3,819 | $30.00 | $114,570.00 | | |
| 2/28/2018 | Rachel Humphrey | Insider | Sell | 23,840 | $30.00 | $715,200.00 | 54,074 | |
| 2/1/2018 | Debanjan Ray | CFO | Sell | 2,548 | $26.69 | $68,006.12 | 4,741 | |
| 1/5/2018 | Frederick W Gluck | Director | Sell | 10,000 | $25.01 | $250,100.00 | | |
| 1/5/2018 | Sean A Mccarthy | Insider | Sell | 6,526 | $25.01 | $163,215.26 | 11,169 | |
| 1/2/2018 | Debanjan Ray | CFO | Sell | 2,500 | $21.11 | $52,775.00 | | |
| 1/2/2018 | Sean A Mccarthy | Insider | Sell | 13,052 | $21.04 | $274,614.08 | 17,695 | |
| 12/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $22.29 | $111,450.00 | | |
| 12/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $20.58 | $51,450.00 | | |
| 12/1/2017 | Sean A Mccarthy | Insider | Sell | 14,340 | $20.60 | $295,404.00 | | |
| 11/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $20.00 | $50,000.00 | 12,126 | |
| 11/1/2017 | Sean A Mccarthy | CEO | Sell | 14,342 | $19.86 | $284,832.12 | 18,587 | |
| 10/4/2017 | Frederick W Gluck | Director | Sell | 10,000 | $24.27 | $242,700.00 | | |
| 10/4/2017 | Robert I Tepper | Major Shareholder | Sell | 24,777 | $24.34 | $603,072.18 | | |
| 10/4/2017 | Sean A Mccarthy | CEO | Sell | 19,120 | $24.13 | $461,365.60 | 23,365 | |
| 10/4/2017 | William Michael Kavanaugh | Insider | Sell | 48,368 | $24.34 | $1,177,277.12 | | |
| 10/2/2017 | Debanjan Ray | CFO | Sell | 2,500 | $18.10 | $45,250.00 | | |
| 10/2/2017 | Sean A Mccarthy | Insider | Sell | 9,562 | $18.57 | $177,566.34 | | |
| 9/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $17.30 | $86,500.00 | | |
| 9/19/2017 | Robert I Tepper | Major Shareholder | Sell | 20,000 | $18.00 | $360,000.00 | 54,293 | |
| 9/1/2017 | Debanjan Ray | CFO | Sell | 2,500 | $17.17 | $42,925.00 | 17,126 | |
| 9/1/2017 | Sean A Mccarthy | Insider | Sell | 9,930 | $17.32 | $171,987.60 | 14,175 | |
| 8/31/2017 | Sean A Mccarthy | Insider | Sell | 18,756 | $17.50 | $328,230.00 | 23,001 | |
| 8/9/2017 | Debanjan Ray | CFO | Sell | 2,500 | $15.00 | $37,500.00 | 19,626 | |
| 8/9/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.00 | $71,715.00 | 9,026 | |
| 7/3/2017 | Debanjan Ray | CFO | Sell | 2,500 | $15.47 | $38,675.00 | 22,126 | |
| 7/3/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.52 | $74,201.12 | 9,026 | |
| 6/29/2017 | Robert I Tepper | Major Shareholder | Sell | 15,000 | $16.00 | $240,000.00 | 44,777 | |
| 6/26/2017 | Frederick W Gluck | Director | Sell | 5,000 | $14.61 | $73,050.00 | | |
| 6/26/2017 | Sean A Mccarthy | Insider | Sell | 4,481 | $15.00 | $67,215.00 | 8,726 | |
| 6/5/2017 | Sean A Mccarthy | Insider | Sell | 300 | $15.00 | $4,500.00 | 4,545 | |
| 5/1/2017 | Sean A Mccarthy | Insider | Sell | 4,781 | $15.70 | $75,061.70 | 6,760 | |
| 4/12/2017 | Kevin P Starr | Major Shareholder | Sell | 28,357 | $16.36 | $463,920.52 | 31,419 | |
| 4/4/2017 | Sean A Mccarthy | Insider | Sell | 9,562 | $17.22 | $164,657.64 | 6,760 | |
| 3/27/2017 | Rock Ventures Lp Third | Major Shareholder | Sell | 1,650,000 | $17.39 | $28,693,500.00 | | |
| 3/20/2017 | Robert C Goeltz II | CFO | Sell | 21,517 | $19.81 | $426,251.77 | 31,306 | |
| 3/20/2017 | Sean A Mccarthy | Insider | Sell | 14,343 | $19.60 | $281,122.80 | 16,322 | |
| 3/3/2017 | Sean A Mccarthy | Insider | Sell | 14,343 | $15.00 | $215,145.00 | 16,322 | |
| 11/28/2016 | Ix L.P. Canaan | Director | Sell | 38,459 | $11.56 | $444,586.04 | | |
| 11/22/2016 | Ix L.P. Canaan | Director | Sell | 42,550 | $11.71 | $498,260.50 | | |
| 11/21/2016 | Ix L.P. Canaan | Director | Sell | 45,324 | $11.61 | $526,211.64 | | |
| 11/16/2016 | Ix L.P. Canaan | Director | Sell | 51,581 | $11.50 | $593,181.50 | | |
| 11/15/2016 | Timothy M Shannon | Director | Sell | 33,064 | $11.48 | $379,574.72 | 268 | |
| 11/14/2016 | Ix L.P. Canaan | Director | Sell | 86,270 | $11.16 | $962,773.20 | | |
| 11/9/2016 | Ix L.P. Canaan | Director | Sell | 13,730 | $11.03 | $151,441.90 | | |
| 6/10/2016 | Timothy M Shannon | Director | Sell | 48,427 | $10.07 | $487,659.89 | 134 | |
| 6/7/2016 | Ix L.P. Canaan | Director | Sell | 111,498 | $10.01 | $1,116,094.98 | | |
| 6/3/2016 | Ix L.P. Canaan | Director | Sell | 59,621 | $10.80 | $643,906.80 | | |
| 6/1/2016 | Ix L.P. Canaan | Director | Sell | 22,463 | $10.75 | $241,477.25 | | |
| 5/27/2016 | Ix L.P. Canaan | Director | Sell | 25,082 | $10.60 | $265,869.20 | | |
| 5/26/2016 | Timothy M Shannon | Director | Sell | 51,343 | $10.34 | $530,886.62 | 134 | |
| 5/24/2016 | Ix L.P. Canaan | Director | Sell | 13,253 | $10.09 | $133,722.77 | | |
| 5/20/2016 | Ix L.P. Canaan | Director | Sell | 8,687 | $10.10 | $87,738.70 | | |
| 10/14/2015 | Cynthia J Ladd | VP | Buy | 3,000 | $12.00 | $36,000.00 | 3,000 | |
| 10/14/2015 | Frederick W Gluck | Director | Buy | 15,000 | $12.00 | $180,000.00 | 147,791 | |
| 10/14/2015 | James E Flynn | Insider | Buy | 625,000 | $12.00 | $7,500,000.00 | | |
(Data available from 1/1/2013 forward)
CytomX Therapeutics (NASDAQ CTMX) News Headlines
| Source: |
|
CytomX Therapeutics (NASDAQ:CTMX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CytomX Therapeutics (NASDAQ:CTMX) Income Statement, Balance Sheet and Cash Flow Statement
CytomX Therapeutics (NASDAQ CTMX) Stock Chart for Saturday, May, 26, 2018
Loading chart…
